AbbVie Inc. (ABBV): Long-Term Debt
$64.50B
As of 2025-12-31
+0.7%
3-year compound annual growth
-5.4%
5-year compound annual growth
| Period ended | Long-Term Debt | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $64.50B | -3.5% | 2026-02-20, Balance as of period end |
| 2024-12-31 | $66.84B | +12.8% | 2025-02-14, Balance as of period end |
| 2023-12-31 | $59.24B | -6.2% | 2024-02-20, Balance as of period end |
| 2022-12-31 | $63.13B | -16.9% | 2023-02-17, Balance as of period end |
| 2021-12-31 | $75.96B | -10.6% | 2022-02-18, Balance as of period end |
| 2020-12-31 | $84.95B | +26.3% | 2021-02-19, Balance as of period end |
| 2019-12-31 | $67.23B | n/a | 2020-02-21, Balance as of period end |
Long-Term Debt at similar companies
| Company | Year ended | Long-Term Debt | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $64.50B | -3.5% |
| Eli Lilly & Co (LLY) | 2024-12-31 | $29.47B | +54.3% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $44.83B | -9.3% |
| Abbott Laboratories (ABT) | 2025-12-31 | $12.93B | -8.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $41.44B | +27.9% |
| Bausch Health Companies Inc. (BHC) | 2025-12-31 | $20.82B | -3.7% |
| Organon & Co. (OGN) | 2025-12-31 | $8.64B | -2.7% |
| BeOne Medicines Ltd. (ONC) | 2025-12-31 | $836.37M | n/a |
| Elanco Animal Health Inc (ELAN) | 2025-12-31 | $3.76B | -12.9% |
Compare ABBV, LLY, BMY, ABT side by side · Screen every company in Pharmaceutical Preparations ↗